News FocusHIV/AIDS

Hedged Bet: An Unusual AIDS Vaccine Trial

See allHide authors and affiliations

Science  12 Aug 2005:
Vol. 309, Issue 5737, pp. 1003
DOI: 10.1126/science.309.5737.1003

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

No one has yet found an AIDS vaccine that can trigger effective antibodies against HIV's surface protein. So Merck has constructed a vaccine that abandons antibodies altogether, and the company is testing it in a fast-tracked study to determine whether it's worth pursuing the approach.